Drug Trial Radar · NCT07061210
An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer
Last checked: Nov 20, 2026Latest source record: Jul 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Jul 1, 2025
Primary completion
Oct 1, 2026
Study completion Jan 1, 2027
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and efficacy of HRS-2189 combined with Adebrelimab and BP102 in the treatment of metastatic colorectal cancer
Conditions
- Colorectal Cancer Metastatic
Interventions
HRS-2189Drug
HRS-2189
AdebrelimabDrug
Adebrelimab
BP102Drug
BP102
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: assessed up to 1 year
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.